CLYC news, looks like the deal is done :-)))
SARASOTA, Fla.--(BUSINESS WIRE)--July 18, 2000--Catalyst
Communications, Inc. (Pink Sheets:CLYC) announced today that it has
acquired privately held DNAPrint genomics Inc., a Sarasota, Florida
based genomic research and personalized medicine corporation.
DNAPrint genomics is developing a cutting edge informatics
platform and knowledge base for the application of human genome
information to personalized medical practice. DNAPrint genomics, Inc.
will focus on the dissection of complex genetic traits through the
study of human genetic variation.
The completion of the Human Genome Project, along with the recent
introduction of automated, high-throughput genotyping hardware
systems, allow for the "mining" of human genome information with
diagnostic or therapeutic value on a scale never before possible. At
present, this data "mining" is accomplished with relatively simple
pattern detection and association tools. These existing tools do
little to unravel the inherently complex etiological patterns,
however, because most human diseases and drug interaction responses
are the result of complex genetic and environmental interactions. In
order to find patterns of complex genetic association, DNAPrint
genomics is developing a unique informatics platform with
unprecedented analytical power.
DNAPrint genomics details
The Phenome(SM) platform system currently being developed by the
Company will allow researchers, physicians and patients to combine
genomic research with individual genetic profiles to define, diagnose
and treat human diseases on a level never before possible. The primary
market for the company's product is the clinical community. As human
genome project technology and information combine to evolve medicine
toward a "patient-centric" model of practice, medical professionals
will define their diagnoses and treatment regimens in terms of a
patient's unique genetic profile. Rather than prescribe drugs, or
diagnose disease, based on average responses or characteristics from
the population, patients of the future will be considered within the
context of their personal genetic make-up, or genotype. The tailoring
of medicine to a patient based on their genotype is known as
personalized, or customized medicine, and this medicine will rely on
systematic and comprehensive analysis of human genetic variation
through SNP (Single Nucleotide Polymorphism) sequencing.
DNAPrint genomics Business
The company will provide practitioners of genomic research and
personalized medicine with a comprehensive system for disease
dissection and patient classification. Physicians will be able to use
the company's system, through a combination of on-site
hardware/software placement and ASP (application-service provider)
resources, to draw highly sophisticated conclusions and associations
between patient genotype data and a knowledge base of pharmacogenomic
and disease "solutions". DNAPrint genomics will use its proprietary
informatics platform to discover these "solutions" that will be used
for patient classification. The analytical heart of the system is a
collection of sophisticated algorithms that enable a gometric
progression from the multivariate dissection of high-density genotype
matrices to multi-dimensional associations with complex human traits.
The system uses a variety of novel mathematical modeling and
programming techniques, which comprise the bulk of the companies
budding intellectual property portfolio. The company has already filed
patent applications for a genetic analysis reagent that confers
considerable advantages for high-throughput DNA sequencing and
genotyping, and has filed applications for five trade and/or service
marks connected with the cocompany business model. The company intends
to patent the application of its informatics platform to the field of
genomic research and for personalized medical applications. The
company also intends to patent a continuously growing portfolio of
genetic "solutions" or diagnostic models that it discovers through the
use of its proprietary informatics platform. The hardware and software
system will be licensed to practicioners of personalized medicine in
the near future. The "solutions" that the company discovers will form
the companies knowledge base product, which will generate license
revenue via an ASP model each time a patient is classified in the
clinic of the near future.
DNAPrint genomics Inc. was founded by a group of scientists with
research and commercial experience in high-level mathematical
modeling, programming and molecular genetics. Combined, the founders
have amassed over 47 years of experience in these fields, published 31
peer-reviewed papers and filed 42 patent applications covering over
350 unique genetic products in 25 different countries. Chief
Scientific officer, Tony Frudakis, Ph.D. stated, " We are pleased to
have consummated this acquisition, which provides us an opportunity to
carry forward our vision of how medicine should be practiced. We
intend to reward our new investors with innovation, imagination and
scientific rigor in this new but difficult field of study ". DNAPrint
genomics, Inc. is located at 1748 Independence Blvd. Suite D1,
Sarasota, FL 34234. For more information about the company, please
visit www.dnaprint.com.
Catalyst Communications, Inc. is in the process of filing its Form
10SB and is attempting to become a reporting company under the
provisions of the Securities Exchange Act of 1934, as amended, so it
will be eligible to be quoted on the NASD's OTC Bulletin Board.
Except for factual statements made herein, the information
contained in this press release consists of forward-looking statements
that involve risks and uncertainties. The Company's actual results
could differ materially from those contained in such statements.
Factors that could cause or contribute to such differences include
unexpected shortages of critical components, rescheduling or
cancellation of customer orders, the timing and market acceptance of
new product introductions by the Company and its competitors, and
general competition and price pressures in the marketplace. Reference
is also made to other factors set forth in the Company's filings with
the Securities and Exchange Commission.
--30--law/mi*
CONTACT: Scientific Inquiries:
DNAPrint genomics Inc., Sarasota
Tony Frudakis, 941/351-4543
or
Investor Inquiries:
Catalyst Communications Inc., Sarasota
Richard Craig Hall, 941/341-0136
KEYWORD: FLORIDA
INDUSTRY KEYWORD: MEDICAL SOFTWARE TELECOMMUNICATIONS
MERGERS/ACQ |
